Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies
Crossref DOI link: https://doi.org/10.1007/s00280-014-2617-3
Published Online: 2014-11-08
Published Print: 2015-01
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Marostica, Eleonora
Sukbuntherng, Juthamas
Loury, David
de Jong, Jan
de Trixhe, Xavier Woot
Vermeulen, An
De Nicolao, Giuseppe
O’Brien, Susan
Byrd, John C.
Advani, Ranjana
McGreivy, Jesse
Poggesi, Italo
Text and Data Mining valid from 2014-11-08